Vivimed Labs Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026, to both BSE Limited and National Stock Exchange of India Limited.

Q4FY26 Compliance Certificate Details

The company forwarded the certificate received from its Registrar and Share Transfer Agent (RTA), Aarthi Consultants Private Limited, a SEBI registered Category-I RTA bearing Registration Number INR000000379. The certificate confirms compliance with dematerialization requirements for the period from January 1, 2026 to March 31, 2026.

RTA Compliance Confirmation

Aarthi Consultants Private Limited confirmed completion of required actions within 15 days of receiving security certificates from depository participants for dematerialization purposes. The RTA verified that dematerialized securities are listed on appropriate stock exchanges, mutilated and cancelled forwarded certificates, and substituted the depository name as registered owner in records.

Stock Exchange Communication

The compliance certificate was addressed to both major Indian stock exchanges where Vivimed Labs shares are traded. BSE Limited received the communication referencing stock code 532660, while National Stock Exchange of India Limited received it under stock code VIVIMEDLAB.

Regulatory Background

The company previously declared to stock exchanges that it does not fall under the classification of a 'large corporate entity' as per SEBI framework established through Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. This latest submission represents ongoing regulatory compliance measures ensuring transparency in depository and participant operations.

Company Information

Vivimed Labs Limited operates with its registered office at Kolhar Industrial Area, Bidar, Karnataka, and maintains its corporate office in Hyderabad, Telangana. The company's CIN is L02411KA1988PLC009465, reflecting its incorporation in Karnataka in 1988.

Vivimed Labs Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, revealing significant operational challenges with widened losses and declining revenue across both standalone and consolidated operations.

Standalone Financial Performance

The pharmaceutical company's standalone operations showed deteriorating performance in Q3 FY26. Revenue from operations declined substantially to ₹116.31 million compared to ₹186.59 million in Q3 FY25, representing a significant year-on-year decrease.

For the nine-month period ended December 31, 2025, the company's financial position remained challenging. Revenue decreased to ₹342.33 million from ₹482.33 million in the corresponding period of FY25, while the net loss increased to ₹295.07 million compared to ₹270.79 million in 9M FY25.

Consolidated Results Mirror Standalone Trends

The consolidated financial results, which include subsidiaries Finoso Pharma Private Limited, Vivimed Holdings Limited, Vivimed Labs USA INC, and Vivimed Labs Mauritius Limited, along with associate Yantra Green Power Private Limited, showed similar performance patterns.

Expense Structure and Cost Management

The company's expense structure revealed several key areas of concern. Total expenses for Q3 FY26 standalone operations reached ₹281.97 million compared to ₹262.64 million in Q3 FY25. Notable expense components included:

• Cost of material consumed: ₹69.57 million
• Employee benefit expenses: ₹26.82 million
• Other expenses: ₹142.41 million
• Depreciation and amortisation: ₹44.02 million
• Finance costs: ₹9.43 million

Auditor Qualifications and Concerns

The statutory auditors SVRL & Co. expressed qualified conclusions on both standalone and consolidated results, highlighting several significant matters:

Key Audit Concerns:

• Unprovided interest, penal interest and charges of approximately ₹164.52 million for Q3 FY26 and ₹472.37 million for nine months ended December 31, 2025
• Ongoing evaluation of forensic audit observations from FY 2022-23
• Commission expense provision of ₹46.03 million relating to earlier financial years requiring additional documentation

Debt and Financial Structure

The company disclosed that total debt from SBI Bank has been assigned to Rare Asset Reconstruction Company (ARC) under SARFAESI Act, 2002. The liability continues to be shown under borrowings and remains payable to RARE ARC. The paid-up equity share capital stood at ₹165.83 million across all reporting periods.

The Board of Directors approved these results at their meeting held on March 13, 2026, with the meeting concluding at 21:30 hours. The results were prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013.